Breaking News Instant updates and real-time market news.

NCNA

NuCana

$18.90

1.9 (11.18%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25

NuCana updated Phase Ib data positive for acelarin in biliary cancer, says Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro notes that NuCana presented updated Phase Ib data for Acelarin plus cisplatin in 1st-line advanced BTC at ESMO this weekend. An ORR of 50% in 14 patients is consistent with the abstract and continues to suggest a near doubling of standard of care, he adds, highlighting that tumor reductions appear to be durable out to the 36-week assessment and the safety profile is unremarkable compared to gem/cis. The analyst maintains his positive outlook for the planned Phase III trial and the opportunity to establish a new standard of care for this sizable patient population. Catanzaro reiterates an Overweight rating and $36 price target on the shares.

  • 21

    Oct

NCNA NuCana
$18.90

1.9 (11.18%)

10/18/18
PIPR
10/18/18
INITIATION
Target $36
PIPR
Overweight
NuCana initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started NuCana with an Overweight rating and $36 price target, stating that data for its lead product, Acelarin, have "strongly" pointed towards platform validation. He sees an opportunity for the drug in platinum-resistant ovarian cancer and sees the potential for it to "establish a new frontline standard of care in biliary tract cancer," Catanzaro tells investors.
10/23/17
WBLR
10/23/17
INITIATION
WBLR
Outperform
NuCana initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started NuCana with an Outperform rating saying her probability-adjusted net present value model derives a fair value of $35 per share at the end of 2018 just based on the company's lead two assets. The analyst forecasts global peak sales of Acelarin in the first four indications, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, biliary cancer, and pancreatic cancer-at GBP 800M with 40%-60% probabilities of success. She estimates NUC-3373 to generate peak sales of GBP 960M in the first two indications, advanced colorectal and breast cancers, with a 20% probability of success.
10/23/17
SBSH
10/23/17
INITIATION
Target $23
SBSH
Buy
NuCana initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started NuCana with a Buy rating and $23 price target. The company's technology platform produces "much-improved versions of decades-old chemo drugs, with minimal innovation risk," the analyst contends.
10/23/17
COWN
10/23/17
INITIATION
COWN
Outperform
NuCana initiated with an Outperform at Cowen

TODAY'S FREE FLY STORIES

GKOS

Glaukos

$71.40

0.31 (0.44%)

05:46
04/26/19
04/26
05:46
04/26/19
05:46
Hot Stocks
Glaukos enters collaboration, distribution agreement with Santen »

Santen Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

, BIIB

Biogen

$229.78

5.46 (2.43%)

05:43
04/26/19
04/26
05:43
04/26/19
05:43
Hot Stocks
Nightstar: ISS, Glass Lewis recommend holders vote 'FOR' deal with Biogen »

Nightstar Therapeutics…

NITE

Nightstar Therapeutics

$25.61

0.08 (0.31%)

BIIB

Biogen

$229.78

5.46 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 04

    May

  • 29

    May

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:41
04/26/19
04/26
05:41
04/26/19
05:41
Earnings
Sanofi backs FY19 business EPS growth of 3%-5% at CER »

Sanofi continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

SNY

Sanofi

$41.27

-0.2 (-0.48%)

05:39
04/26/19
04/26
05:39
04/26/19
05:39
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.28 »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 31

    May

  • 26

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:36
04/26/19
04/26
05:36
04/26/19
05:36
Earnings
AstraZeneca backs FY19 core EPS view of $3.50-$3.70 »

Backs FY19 product sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

AZN

AstraZeneca

$39.07

0.35 (0.90%)

05:32
04/26/19
04/26
05:32
04/26/19
05:32
Earnings
AstraZeneca reports Q1 reported EPS 47c, consensus 42c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 07

    May

  • 31

    May

  • 20

    Jun

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

05:29
04/26/19
04/26
05:29
04/26/19
05:29
Recommendations
Pros Holdings analyst commentary  »

Pros Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ILMN

Illumina

$318.91

4.47 (1.42%)

05:27
04/26/19
04/26
05:27
04/26/19
05:27
Recommendations
Illumina analyst commentary at Piper Jaffray »

Illumina earnings selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

ALGT

Allegiant Travel

$139.70

6.33 (4.75%)

05:22
04/26/19
04/26
05:22
04/26/19
05:22
Recommendations
Allegiant Travel analyst commentary at Imperial Capital »

Allegiant Travel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

NFLX

Netflix

$368.20

-5.99 (-1.60%)

05:19
04/26/19
04/26
05:19
04/26/19
05:19
Recommendations
Netflix analyst commentary at Imperial Capital »

Imperial trims Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

05:16
04/26/19
04/26
05:16
04/26/19
05:16
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

05:11
04/26/19
04/26
05:11
04/26/19
05:11
Downgrade
Starbucks rating change at Wells Fargo »

Starbucks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Hot Stocks
Roche, Spark Therapeutics withdraw, refile premerger notification »

Roche (RHHBY) and Spark…

RHHBY

Roche

$0.00

(0.00%)

ONCE

Spark Therapeutics

$111.40

0.73 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    May

  • 04

    May

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

VCRA

Vocera

$31.31

0.36 (1.16%)

05:10
04/26/19
04/26
05:10
04/26/19
05:10
Recommendations
Vocera analyst commentary at Piper Jaffray »

Vocera positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

  • 05

    Jun

ESPR

Esperion

$43.02

1.14 (2.72%)

05:06
04/26/19
04/26
05:06
04/26/19
05:06
Upgrade
Esperion rating change  »

Esperion upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

MDCO

The Medicines Co.

$29.84

0.37 (1.26%)

05:05
04/26/19
04/26
05:05
04/26/19
05:05
Upgrade
The Medicines Co. rating change  »

The Medicines Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 08

    May

RS

Reliance Steel

$91.29

2.46 (2.77%)

05:03
04/26/19
04/26
05:03
04/26/19
05:03
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TAL

TAL Education

05:02
04/26/19
04/26
05:02
04/26/19
05:02
Downgrade
TAL Education rating change  »

TAL Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASAZY

Assa Abloy

$0.00

(0.00%)

05:01
04/26/19
04/26
05:01
04/26/19
05:01
Downgrade
Assa Abloy rating change at Jefferies »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BKU

BankUnited

$36.10

-0.39 (-1.07%)

05:00
04/26/19
04/26
05:00
04/26/19
05:00
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TIGO

Millicom

$57.40

-1.25 (-2.13%)

04:59
04/26/19
04/26
04:59
04/26/19
04:59
Upgrade
Millicom rating change  »

Millicom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$151.26

-5.52 (-3.52%)

04:56
04/26/19
04/26
04:56
04/26/19
04:56
Upgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AXTA

Axalta Coating

$26.71

0.21 (0.79%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Downgrade
Axalta Coating rating change  »

Axalta Coating downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

KRP

Kimbell Royalty Partners

$18.00

0.02 (0.11%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

CYAD

Celyad

$20.60

(0.00%)

04:55
04/26/19
04/26
04:55
04/26/19
04:55
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.